Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches
- PMID: 25873269
- PMCID: PMC4478204
- DOI: 10.1002/stem.2039
Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches
Abstract
Cancer stem cells (CSCs) represent a small subset of tumor cells which have the ability to self-renew and generate the diverse cells that comprise the tumor bulk. They are responsible for local tumor recurrence and distant metastasis. However, they are resistant to conventional radiotherapy and chemotherapy. Novel immunotherapeutic strategies that specifically target CSCs may improve the efficacy of cancer therapy. To immunologically target CSC phenotypes, innate immune responses to CSCs have been reported using Natural killer cells and γδ T cells. To target CSC specifically, in vitro CSC-primed T cells have been successfully generated and shown targeting of CSCs in vivo after adoptive transfer. Recently, CSC-based dendritic cell vaccine has demonstrated significant induction of anti-CSC immunity both in vivo in immunocompetent hosts and in vitro as evident by CSC reactivity of CSC vaccine-primed antibodies and T cells. In addition, identification of specific antigens or genetic alterations in CSCs may provide more specific targets for immunotherapy. ALDH, CD44, CD133, and HER2 have served as markers to isolate CSCs from a number of tumor types in animal models and human tumors. They might serve as useful targets for CSC immunotherapy. Finally, since CSCs are regulated by interactions with the CSC niche, these interactions may serve as additional targets for CSC immunotherapy. Targeting the tumor microenvironment, such as interrupting the immune cell, for example, myeloid-derived suppressor cells, and cytokines, for example, IL-6 and IL-8, as well as the immune checkpoint (PD1/PDL1, etc.) may provide additional novel strategies to enhance the immunological targeting of CSCs.
Keywords: Cancer stem cells; Cytotoxic T lymphocytes; Immunotherapy; Lymphocytes.
© 2015 AlphaMed Press.
Figures
Similar articles
-
Immunologic Targeting of Cancer Stem Cells.Surg Oncol Clin N Am. 2019 Jul;28(3):431-445. doi: 10.1016/j.soc.2019.02.010. Epub 2019 Apr 10. Surg Oncol Clin N Am. 2019. PMID: 31079798 Review.
-
Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells.Immunotherapy. 2010 Mar;2(2):201-11. doi: 10.2217/imt.10.10. Immunotherapy. 2010. PMID: 20635928 Review.
-
Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells.Stem Cells. 2015 Feb;33(2):354-66. doi: 10.1002/stem.1850. Stem Cells. 2015. PMID: 25267273
-
Evolving Strategies for Therapeutically Targeting Cancer Stem Cells.Adv Cancer Res. 2016;131:159-91. doi: 10.1016/bs.acr.2016.04.003. Epub 2016 Jun 3. Adv Cancer Res. 2016. PMID: 27451127 Review.
-
[Identification of cancer-stem cell antigens and development of CTL-mediated cancer immunotherapy].Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(1):40-47. doi: 10.2177/jsci.40.40. Nihon Rinsho Meneki Gakkai Kaishi. 2017. PMID: 28539553 Review. Japanese.
Cited by
-
Distribution of cancer stem cells in two human brain gliomas.Oncol Lett. 2019 Feb;17(2):2123-2130. doi: 10.3892/ol.2018.9824. Epub 2018 Dec 12. Oncol Lett. 2019. PMID: 30719107 Free PMC article.
-
Therapies targeting cancer stem cells: Current trends and future challenges.World J Stem Cells. 2015 Oct 26;7(9):1185-201. doi: 10.4252/wjsc.v7.i9.1185. World J Stem Cells. 2015. PMID: 26516409 Free PMC article. Review.
-
Epigenetics in cancer stem cells.Mol Cancer. 2017 Feb 1;16(1):29. doi: 10.1186/s12943-017-0596-9. Mol Cancer. 2017. PMID: 28148257 Free PMC article. Review.
-
A Breast Cancer Stem Active Cobalt(III)-Cyclam Complex Containing Flufenamic Acid with Immunogenic Potential.Angew Chem Int Ed Engl. 2024 Feb 5;63(6):e202317940. doi: 10.1002/anie.202317940. Epub 2023 Dec 29. Angew Chem Int Ed Engl. 2024. PMID: 38063406 Free PMC article.
-
Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy.Oncoimmunology. 2020 Jun 16;9(1):1779991. doi: 10.1080/2162402X.2020.1779991. Oncoimmunology. 2020. PMID: 32934883 Free PMC article. Review.
References
-
- Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66:9339–9344. - PubMed
-
- Al-Hajj M, Becker MW, Wicha M, et al. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev. 2004;14:43–47. - PubMed
-
- Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275–284. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous